Prognosis Value of Pro-adrenomedullin in Acute Exacerbations of COPD in ER

Usefulness of Pro-adrenomedullin (MR proADM)as a Predictor of Outcome in Acute Exacerbations of COPD Visiting the Emergency Room

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01857947

Acronym

UTAPE BPCO

Enrollment

370

Registered

2013-05-20

Start date

2013-03-31

Completion date

2014-12-31

Last updated

2014-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Disease, Chronic Obstructive Patients Admitted in Emergency Department for Acute Exacerbation

Keywords

AECOPD Mr ProADM Biomarkers ER Outcome

Brief summary

The purpose of this study is to determine whether pro-adrenomedullin (Mr proADM)in addition to clinical evaluation is effective to predict outcome of acute exacerbations of COPD patients visiting the emergency room(ER).

Detailed description

Acute exacerbation of COPD (AECOPD)are usual and frequent cause of admission in emergency room (ER). No validated clinical or biological predictor of evolution are available. The main objective is to determine the prognosis value of Mr proADM in addition to the clinical risk stratification for AE COPD patients in ER. Patients presenting with a AECOPD diagnosis in ER will have a blood sample collected and freezed at their admission. Mr proADM will be assessed at the end of the study. Clinicians in charge of patients will not have the result during the management of their patients. This study implies no change in the patients' management. Data related to the patients'demographic,current exacerbation and basic COPD characteristics will be collected.

Interventions

OTHERAECOPD Mr proADM

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients \> 40 years old * Acute exacerbation of COPD

Exclusion criteria

* Medico social conditions not allowing home discharge * Other causes of Dyspnea: Pneumothorax, pulmonary embolism, pulmonary oedema, lung cancer * Pneumonia on chest ray * acute respiratory distress requiring immediate ICU transfer

Design outcomes

Primary

Measure	Time frame	Description
composite outcome measure	at Day 30	Death, subsequently transfer to ICU, relapse, need to be ventilated after 24 hours of their admission in ER

Secondary

Measure	Time frame	Description
composite outcome	at Day 7 of ER admission	Death, subsequently transfer to ICU, relapse, need to be ventilated after 24 hours of their admission in ER
correlation between Mr proADM and patients Severity	at Day 7 and Day 30 of ED admission	Correlation between MR proADM and patient's severity

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026